Skip to content

Study · Non-randomized trial · 2026

6 results

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial.

Raaschou-Oddershede D, Schwarz CR, Kovalova T, Branch KR, Del Prato S, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N, Gerstein HC

Diabetes, obesity & metabolism1 Jul 2026Cited by 1 (Europe PMC)

PMID42387302 (opens in a new tab)PMCIDPMC13448972 (opens in a new tab)DOI10.1111/dom.71062 (opens in a new tab)PepBankPUB-42387302
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    Efpeglenatide modified changes in HbA1c, weight, pulse pressure, LDL cholesterol, UACR, eGFR, heart rate, lipase, and amylase.

    In plain wordsEfpeglenatide modified changes in HbA1c, weight, pulse pressure, LDL cholesterol, UACR, eGFR, heart rate, lipase, and amylase.

    Peptide
    Efpeglenatide
    Outcome
    Direction not reportedChanges in clinical variables and biomarkers
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Change in HbA1c, weight, pulse pressure, LDL cholesterol, urinary albumin: creatinine ratio (UACR), eGFR, heart rate, lipase and amylase were modified by efpeglenatide.
    1 context sentence
    Summary · context
    This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables and biomarkers during the trial might explain the observed reduction in MACE.
  2. 02HumanObservational studyMechanism

    In the trial mediation analysis, HbA1c changes statistically accounted for 14% of efpeglenatide's MACE effect in univariable analysis.

    In plain wordsThe trial analysis estimated that HbA1c changes explained 14% of efpeglenatide's effect on major cardiovascular events.

    Peptide
    Efpeglenatide
    Outcome
    Not applicableMACE effect mediation by HbA1c
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mediation
    14%
    HbA1c, univariable

    Source sentences

    Summary
    Of these, univariable analyses showed that only changes in HbA1c, LDL cholesterol, UACR and amylase accounted for 14%, 11%, 16% and 10%, respectively, of the effect of efpeglenatide on MACE.
    1 context sentence
    Summary · context
    This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables and biomarkers during the trial might explain the observed reduction in MACE.
  3. 03HumanObservational studyMechanism

    In the trial mediation analysis, LDL cholesterol changes statistically accounted for 11% of efpeglenatide's MACE effect in univariable analysis.

    In plain wordsThe trial analysis estimated that LDL cholesterol changes explained 11% of efpeglenatide's effect on major cardiovascular events.

    Peptide
    Efpeglenatide
    Outcome
    Not applicableMACE effect mediation by LDL cholesterol
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mediation
    11%
    LDL cholesterol, univariable

    Source sentences

    Summary
    Of these, univariable analyses showed that only changes in HbA1c, LDL cholesterol, UACR and amylase accounted for 14%, 11%, 16% and 10%, respectively, of the effect of efpeglenatide on MACE.
    1 context sentence
    Summary · context
    This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables and biomarkers during the trial might explain the observed reduction in MACE.
  4. 04HumanObservational studyMechanism

    In the trial mediation analysis, UACR changes statistically accounted for 16% of efpeglenatide's MACE effect in univariable analysis.

    In plain wordsThe trial analysis estimated that urine albumin-to-creatinine ratio changes explained 16% of efpeglenatide's effect on major cardiovascular events.

    Peptide
    Efpeglenatide
    Outcome
    Not applicableMACE effect mediation by UACR
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mediation
    16%
    UACR, univariable

    Source sentences

    Summary
    Of these, univariable analyses showed that only changes in HbA1c, LDL cholesterol, UACR and amylase accounted for 14%, 11%, 16% and 10%, respectively, of the effect of efpeglenatide on MACE.
    1 context sentence
    Summary · context
    This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables and biomarkers during the trial might explain the observed reduction in MACE.
  5. 05HumanObservational studyMechanism

    In the trial mediation analysis, amylase changes statistically accounted for 10% of efpeglenatide's MACE effect in univariable analysis.

    In plain wordsThe trial analysis estimated that amylase changes explained 10% of efpeglenatide's effect on major cardiovascular events.

    Peptide
    Efpeglenatide
    Outcome
    Not applicableMACE effect mediation by amylase
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mediation
    10%
    amylase, univariable

    Source sentences

    Summary
    Of these, univariable analyses showed that only changes in HbA1c, LDL cholesterol, UACR and amylase accounted for 14%, 11%, 16% and 10%, respectively, of the effect of efpeglenatide on MACE.
    1 context sentence
    Summary · context
    This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables and biomarkers during the trial might explain the observed reduction in MACE.
  6. 06HumanObservational studyMechanism

    In the trial mediation analysis, LDL cholesterol and UACR jointly accounted for 29.6% mediation of efpeglenatide's MACE effect.

    In plain wordsThe trial analysis estimated that LDL cholesterol and urine albumin-to-creatinine ratio together explained 29.6% of efpeglenatide's cardiovascular effect.

    Peptide
    Efpeglenatide
    Outcome
    Not applicableJoint MACE effect mediation by LDL cholesterol and UACR
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mediation
    29.6%
    LDL cholesterol and UACR, multivariable

    Source sentences

    Summary
    In the multivariable analysis, LDL cholesterol together with UACR accounted for 29.6% mediation of this effect.
    1 context sentence
    Summary · context
    This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables and biomarkers during the trial might explain the observed reduction in MACE.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.